Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Background: \- In allogeneic stem cell transplantation (SCT), stem cells are taken from a donor and given to a recipient. Sometimes the recipient's immune system destroys the donors' cells. Or donor immune cells attack the recipient's tissues, called graft-versus-host disease (GVHD). This is less likely when the recipient and donor have similar human leukocyte antigens (HLA). Researchers want to see if the drug palifermin improves the results of allogeneic SCT from HLA-matched unrelated donors. Objective: \- To see if high doses of palifermin before chemotherapy are safe, prevent chronic GVHD, and improve immune function after transplant. Eligibility: \- Adults 18 years of age or older with blood or bone marrow cancer with no HLA-matched sibling donor, but with a HLA-matched unrelated donor. Description of Research Study: * Participants will be screened with medical history, physical exam, and blood and urine tests. They will have scans and heart and lung exams. * Before transplant, participants will: * Have many tests and exams.

Introduction: The majority of leukemia patients are acute leukemia patients, so that about 70.8% lymphoblastic leukemia were acute lymphoblastic leukemia (ALL) patients and 66.4 % of myeloid leukemia patients were acute myeloid leukemia (AML) in Tehran metropolitan. During the last two decades, intensification of therapy by the use of high-dose Cytarabine allogeneic stem cell transplantation in selected cases, paralleled by improvement in supportive care may have contributed to the impotent. In this article we use parametric survival models for recognizing prognostic factors in acute leukemia patients. Patients and methods: Data on patients who underwent bone marrow or peripheral blood transplantation were obtained from the Hematology- Oncology and bone marrow transplantation research center at Shariati hospital, Tehran, Iran. Transplantations were performed between Oct. 17, 1993 to Jan. 31, 2007. Written informed consents for hematopoietic cell collection and transplantation were obtained from patients and donors. The study included patients 2 to 56 years of age who had received either an HLA-matched marrow transplant or a marrow transplant with a single HLA mismatch from an unrelated donor. The mean follow- up period was about 2 years after transplantation. Results: Five hundred and seven patients were included in the study. There were 301 with acute myeloid leukemia (AML) and 206 with acute lymphoblastic leukemia (ALL). The median ages of the AML and ALL patients were 27 (

"nIntroduction: The majority of leukemia patients are acute leukemia patients, so that about 70.8% lymphoblastic leukemia were acute lymphoblastic leukemia (ALL) patients and 66.4 % of myeloid leukemia patients were acute myeloid leukemia (AML) in Tehran metropolitan. During the last two decades, intensification of therapy by the use of high-dose Cytarabine allogeneic stem cell transplantation in selected cases, paralleled by improvement in supportive care may have contributed to the impotent. In this article we use parametric survival models for recognizing prognostic factors in acute leukemia patients. "nPatients and methods: Data on patients who underwent bone marrow or peripheral blood transplantation were obtained from the Hematology- Oncology and bone marrow transplantation research center at Shariati hospital, Tehran, Iran. Transplantations were performed between Oct. 17, 1993 to Jan. 31, 2007. Written informed consents for hematopoietic cell collection and transplantation were obtained from patients and donors. The study included patients 2 to 56 years of age who had received either an HLA-matched marrow transplant or a marrow transplant with a single HLA mismatch from an unrelated donor. The mean follow- up period was about 2 years after transplantation. "nResults: Five hundred and seven patients were included in the study. There were 301 with acute myeloid leukemia (AML) and 206 with acute lymphoblastic leukemia (ALL). The median ages of the AML and ALL patients wer

Data on 281 patients with chronic myelogenous leukemia who received bone marrow transplants were analysed. The median follow-up time was 40 months; 170 patients were in first chronic phase, 14 were in second chronic phase, 73 were in accelerated phase and 24 were in blastic crisis. The overall actuarial survival was 50% at 5 years. In multivariate analyses, the probability of relapse correlated with the phase of the disease, the method of total body irradiation, the T cell depletion of the marrow and the occurrence of a chronic graft-versus-host disease (GVHD). The probability of survival was better for patients with grade 0-1 GVHD than for patients with grade 2-4 GVHD. In contrast, the probability of disease-free survival was significantly better for patients who received a non-T cell-depleted marrow than for recipients of T cell-depleted marrow. Interval between diagnosis and transplant, splenectomy before transplant, patient age and donor recipient sex match were not significantly associated with outcome. Bone marrow transplantation in first chronic phase with an HLA identical non-T cell depleted marrow offers the better chance of prolonged leukemia-free survival.

High resolution typing of the HLA-DPB1 locus for patient who requested for hematopoietic stem cell transplantation (HSCT) workup has recently become mandatory by the National Marrow Donor Program (NMDP) in order to facilitate matching between donors and recipients for better outcomes. The likelihood of identifying HLA matched donors in Hong Kong, on top of the existing HLA-A, -B, -C, and -DRB1 loci, is revisited in this study. HLA-A, -B, -C, -DRB1 and -DPB1 genotypes of 5,266 volunteer unrelated Chinese donors from the Hong Kong Bone Marrow Donor Registry (HKBMDR), were included in this study. Matching models were employed to determine the matching probabilities for 10/10(DPB1) and 9/10(DPB1) HLA match. The matching probabilities are 20% at 10/10(DPB1) HLA match and 55% at 9/10(DPB1) match, based on the existing 130,000 donors in the HKBMDR. The likelihoods of match become 27% and 65% respectively, by increasing the registry to 250,000. However, if DPB T-cell-epitope (TCE) model is considered in the matching, the probability will increase to 46% at 10/10 DPB1 permissive mismatching. Our findings provide vital information about the future planning on the targeted recruitment size, HLA typing and search strategies of the donor registry and arose the transplant physicians’ acceptability to 9/10(DBP1) or 10/10(DBP1) HLA match. Nevertheless, the marrow donor registry has planned for increasing the registry size and bringing down the age of recruited donors which will ultimately en

Aim Bone marrow (BM) donors and their recipients need not have a matching blood type. Eventually, the BM recipient will become the blood type of the BM donor. This scenario can become quite a conundrum if the BM recipient becomes a patient in need of an organ transplant. In order for a patient to receive a donor organ, the patient and donor’s blood type and HLA typing must be compatible. Methods Blood type was determined using gel test cards. HLA typing was determined by using sequence-specific oligonucleotide (SSO), sequence-specific primer (SSP), and sequence based typing (SBT) technologies. Results Patient #1, originally typed as an A2, had 1 bone marrow donor and 2 cord blood transplants. One of the cord blood transplants successfully engrafted. The engrafted cord blood was from a type O donor. Patient #1 is now typing as type O. Patient #2 was originally typed as A2 and received a bone marrow transplant from a type B donor. Patient #2 is now front-typing as a B and back-typing as an AB. The patient now has an HLA and ABO identical kidney match (his father who is a type B). Previously, the patient and his father were ABO incompatible. Conclusions The ABO and HLA results on both patient #1 and patient #2 indicate that the BM transplants have engrafted. Results also indicate that the ABO and HLA now match that of the donor and differs from the recipient’s original ABO and HLA type. Due to various reasons, for example, a side effect of the immunosuppression, both patients no